RxDoctor Payments Data

Alain Rizkallah, MD

Cardiovascular Disease · Marshfield, WINPI 1861802563

Payments from drug & device makers

$1,958in general payments, 2019–2025

Across 15 payments — averaging $130.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Astellas Pharma US Inc$198
  • CSL Behring$23
  • Novartis$17
  • Boehringer Ingelheim$15
  • Pfizer$14

What the payments were for

  • Travel & lodging$1,40872%
  • Food & beverage$1699%
  • Education$38119%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,958 in reported general payments places this provider in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$108,739
Medicare patients
1,416
Services billed
2,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$270,463
XareltoRivaroxaban54$80,956
MultaqDronedarone Hcl39$55,618
Repatha SureclickEvolocumab58$42,373
BrilintaTicagrelor39$30,051
EntrestoSacubitril/Valsartan31$27,434
Repatha PushtronexEvolocumab13$8,697
Dofetilide52$6,653
Repatha SyringeEvolocumab12$6,438
Metoprolol Succinate223$3,564
Ranolazine ErRanolazine29$1,971
Ezetimibe97$1,653
Atorvastatin Calcium194$1,487
Diltiazem 24hr Er (Cd)Diltiazem Hcl46$1,329
Rosuvastatin Calcium120$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$270,463244 claims
NovartisEntresto$17$27,43431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Marshfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →